Latest / The Founder's Journey with Fexingo: First-Time Entrepreneurs, Failures, and Lessons Learned / From Rejected Pitch to 50M Biotech Data Platform
Transcript
- Lucas: So, there's a biotech data company out of Boston that just crossed fifty million in annual recurring revenue, and the whole thing started with a pitch that got laughed out of a room. Luna: Laughed out? That's a strong reaction. What were they pitching? Lucas: The founders were two bioinformatics PhDs, and they'd built a tool to make clinical trial data more transparent. They thought if patients and researchers could see all the data from failed trials, the whole industry would speed up. They pitched it to a panel of pharma executives, and one of them literally said, 'We don't pay for transparency, we pay for results.' Luna: Ouch. That's brutal. But also, kind of the reality of pharma. Lucas: Exactly. They walked out of that meeting with no funding, but with a very clear signal that their product was solving a problem nobody wanted to pay for. So they went back to the drawing board. Lucas: They started talking to researchers, and kept hearing the same complaint: getting data out of different lab systems is a nightmare. Every machine, every software, every institution has its own format. A researcher might spend six months just cleaning and standardizing data before they can even analyze it. Luna: So they shifted from transparency to interoperability. Lucas: Right. They built a platform that automatically ingests raw data from any source, standardizes it, and makes it queryable. No more manual cleaning. They went back to the same pharma exec who rejected them, and he became their first paying customer. Luna: Ha. There's a nice symmetry there. Lucas: They raised a seed round, and by 2023 they were doing a couple million in revenue. But the real inflection point came in late 2024, when a major pharmaceutical company signed a multi-year deal worth forty million. Luna: That's a huge leap. What changed? Lucas: A few things. One, they had a killer case study with that first pharma company. Two, they got regulatory clarity — the FDA started encouraging more standardized data submissions, and their platform became a way to future-proof. And three, they hired a sales team that actually understood the pharma buying cycle. Luna: Tell me about that sales cycle. It's not like selling software to a startup. Lucas: No, it's a nine-to-eighteen-month process. You have to get through compliance, IT security, legal, and then the scientific team. They learned to start with the scientists, not the procurement people. If the lead researcher loves the tool, they'll fight for the budget. Luna: That's a smart approach. So they're at fifty million now, but I read that they almost ran out of money in 2023? Lucas: Yeah, it was touch and go. They had a Series A that was supposed to close in Q1, but the investor pulled out at the last minute. They had to cut expenses and take on a bridge loan just to make payroll. Luna: What did they cut? Lucas: They laid off half their engineering team and paused all new feature development. They literally focused on keeping the existing customers happy and closing the deals that were in the pipeline. It was a survival mode that forced them to be very disciplined about what the product actually needed to do. Luna: It’s almost like the rejection forced them to get lean and mean. Lucas: Exactly. And that discipline paid off. The bridge loan came from a strategic investor who saw the potential, and they closed the Series A later that year. But the whole experience shaped their company culture. They're famously frugal — they still fly economy and use co-working spaces. Luna: So what's the most surprising thing about this success? I mean, fifty million in ARR is no joke. Lucas: I think the most surprising thing is how niche they stayed. They didn't try to be a general data platform. They're specifically focused on genomics and clinical data. That focus is what let them build deep integrations and trust with pharma companies. Luna: But is that a ceiling? I mean, pharma is a finite market. Lucas: It's a huge finite market — the global pharma R&D spend is over two hundred billion dollars a year. And they're expanding into companion diagnostics and personalized medicine. The data problem is only getting bigger. Luna: So they're not just a startup that survived a rejection; they're a startup that used rejection to find a better fit. Lucas: That's the lesson right there. Rejection is just data. It's feedback. The founders I respect are the ones who treat a 'no' like a diagnostic, not a verdict. Luna: And that's a mindset that applies way beyond biotech. Every founder will face rejection at some point. Lucas: Absolutely. And you know, we talk about this a lot on the show — the value of learning from failure. It's why we don't run ads here. We want to keep these conversations accessible to anyone who's building something, and listener support is what makes that possible. Luna: Yeah, it's a simple model: if you get value from the show, you can support it at buy me a coffee dot com slash fexingo. Lucas: No pressure, but it helps us stay independent and ad-free. Now, back to the biotech founders — there's another angle that's really interesting: the data standards war. Luna: The standards war? Tell me more. Lucas: So, there are competing data formats — FHIR, HL7, even some proprietary ones. The pharma industry hasn't settled on one standard. This platform basically abstracts that away. They support all the major ones, so you don't have to pick a side. Luna: That's actually a huge value proposition. You're the Switzerland of biotech data. Lucas: Exactly. And it's a defensible moat because building those connectors is tedious work. It takes time and domain expertise. You can't just spin up a tech company and do this overnight. Luna: So what's the takeaway for a founder in a completely different industry? Say you're building a SaaS for restaurants or something. Lucas: The takeaway is: find the pain that's so specific that nobody's built a good solution. Then make it ridiculously easy to adopt. Don't boil the ocean. Lucas: And if you get rejected, ask for the 'why'. The pharma exec's answer was the best market research they ever got. Luna: That's a great line. Do you think they ever sent that exec a thank-you card? Lucas: I think they did better than that — they sent him a contract. Luna: Ha. Good point. So what's next for them? I saw they just raised a Series B. Lucas: They did, fifty million at a four hundred million valuation. They're using it to expand into Europe and to build ai powered data quality checks. The founders say their mission is to cut the time it takes to bring a new drug to market by a year. Luna: That's an ambitious goal. But if they can do that, the impact is enormous. Lucas: And it all started with a pitch that got laughed out of a room. A reminder that 'no' is often just the beginning of the conversation. Luna: Well said. That's a wrap for today. Thanks for listening, and we'll see you next time.